Except for traditional treatment using BCG bladder irrigation, recently, immunotherapy targeting immune checkpoints CTLA-4 and PD-1/PD-L1 has been applied to treat early-stage bladder cancer, achieving satisfactory clinical efficacy (7, 38, 39). The gene discussed is PDCD1; the disease is urinary bladder carcinoma.